


Product Name : Rigosertib sodium
Cat. No. : PC-42851
CAS No. : 592542-60-4
Molecular Formula : C₂₁H₂₄NNaO₈S
Molecular Weight : 473.4719
Target : Polo-like Kinase (PLK)
Solubility : H₂O: ≥ 52 mg/mL



Biological Activity

Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive **PLK1** inhibitor (IC₅₀=9-10 nM), selectively induces mitotic G₂/M arrest and apoptosis in cancer cells.

Rigosertib also exhibits inhibitory activity against PDGFR, Abl, and Flt-1, at higher concentrations, inhibits CDK1, Plk2, Src, and Fyn.

Rigosertib demonstrates in vitro cytotoxicity against DU145 and K562 cells with IC₅₀ of 100 and 15 nM.

Rigosertib potently inhibits tumor growth in a variety of xenograft nude mouse models, does not exhibit hematotoxicity, liver damage, or neurotoxicity shows strong synergy with several chemotherapeutic agents.

References

Reddy MV, et al. *J Med Chem.* 2011 Sep 22;54(18):6254-76.

Gumireddy K, et al. *Cancer Cell.* 2005 Mar;7(3):275-86.

Oussenko IA, et al. *Cancer Res.* 2011 Jul 15;71(14):4968-76.

Chun AW, et al. *Cancer Chemother Pharmacol.* 2009 Dec;65(1):177-86.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com